GSK PLC raised its guidance after third-quarter net profit rose mainly due to the U.S. launch of its Arexvy vaccine, although it missed analysts’ forecasts.

The British pharmaceutical giant said Wednesday that net profit from continuing operations for the third quarter was 1.46 billion pounds ($1.77 billion), boosted by the vaccine for respiratory syncytial virus, or RSV, compared with GBP759 million a year earlier and a company-compiled consensus of GBP1.87 billion.